ARTICLE

FindCenter AddIcon

Seismic Sisters: Fighting Stigma of Psychedelics with Science - An Interview with Natalie Ginsberg, Policy and Advocacy Director at Multidisciplinary Association for Psychedelic Studies

By Jessica Semaan — 2020

Society has started to become more accepting of our work and MAPS’ goal of mainstreaming psychedelic medicine seems closer than ever to being achieved,” explains MAPS Policy and Advocacy Director Natalie Ginsberg, M.S.W., in an interview with Jessica Semaan of Seismic Sisters. During the interview, Ginsberg shares her perspectives about the shift in acceptance towards the therapeutic potential of psychedelics, expresses her passion for drug policy, and explains what led her to work at MAPS.

Read on maps.org

FindCenter Post-Image

An Introduction to MDMA

Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.

FindCenter AddIcon
FindCenter Post-Image

An Introduction to LSD

LSD, or lysergic acid diethylamide, is a synthetic drug with potent psychedelic properties. Commonly known as acid, it was originally derived from compounds found in ergot, a fungus that grows on rye.

FindCenter AddIcon
FindCenter Post-Image

Inside The Movement To Decolonize Psychedelic Pharma

As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.

FindCenter AddIcon
FindCenter Post-Image

A Brief History of Psychedelic Psychiatry

In the 1950s a group of pioneering psychiatrists showed that hallucinogenic drugs had therapeutic potential, but the research was halted as part of the backlash against the hippy counterculture.

FindCenter AddIcon
FindCenter Post-Image

Integration, Rippling

In the deep space of the psychedelic experience exists a teaching on unity principle and belonging with the earth.

FindCenter AddIcon
FindCenter Post-Image

Psychedelic Therapy and Racial Trauma: Offering Clients a Deeper Experience of Healing

Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.

FindCenter AddIcon
FindCenter Post-Image

The Cost of Exclusion in Psychedelic Research

In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants.

FindCenter AddIcon
FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

FindCenter AddIcon

EXPLORE TOPIC

Psychedelic Research